JOHAN VERBEECK, DVM
VICE PRESIDENT
JANSSEN BUSINESS DEVELOPMENT
ONCOLOGY
Johan Verbeeck, DVM is Vice President, Janssen Business Development, Oncology where he leads business development planning in support of the Oncology Therapeutic Area. His responsibilities include overseeing transactions and acquisitions, as well as scientific licensing and alliance management with strategic partners.
Johan joined Johnson & Johnson in 1996, through Janssen Pharmaceutica in Belgium, in the Department of Animal Health and subsequently worked in Toxicology, where he served as Study Director for several small molecule development projects. In 2005, Johan joined Tibotec, as Lead Toxicologist for the development of darunavir and etravirine, the company’s first two approved anti-HIV drugs. At the same time, he was Preclinical Development Leader for bedaquiline, the first new drug in development for tuberculosis in over 40 years. In 2007, after the approval of etravirine, Johan became Head of Toxicology Sciences for Janssen Research & Development, LLC. He also served as Alliance Manager in the External Alliances and Business Models group.
Most recently, Johan served as Vice President, Janssen Business Development, Immunology, leading transactions, acquisitions, scientific licensing, and alliance management. His team completed multiple transactions, including the acquisition of Momenta Pharmaceuticals in 2020. Prior to joining the Janssen Business Development team, Johan supported the London Innovation Center and played an active role in helping to establish the center, building its European network, and securing several transactions.
Johan holds a Doctorate in Veterinary Medicine from the University of Gent, Belgium. He also graduated Cum Laude with a Master of Science in Applied Toxicology from the University of Surrey, United Kingdom.